Share

November 01, 2016; 87 (18) NeuroImages

Wernicke encephalopathy

SWI detects petechial hemorrhages in mammillary bodies in vivo

Elke Hattingen, Aline Beyle, Andreas Müller, Thomas Klockgether, Cornelia Kornblum
First published October 31, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003294
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
596

Share

Article Information

vol. 87 no. 18 1956-1957
DOI: 
https://doi.org/10.1212/WNL.0000000000003294
PubMed: 
27799475
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published October 31, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Elke Hattingen, MD, PhD,
    2. Aline Beyle, MD,
    3. Andreas Müller, MD,
    4. Thomas Klockgether, MD, PhD and
    5. Cornelia Kornblum, MD, PhD
  1. Elke Hattingen, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Aline Beyle, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Andreas Müller, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Thomas Klockgether, MD, PhD and
    5. Scientific Advisory Boards:

    1. The Cerebellum, Parkinsonism & Related Disorder, ataxia lay organizations.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Section Editor Exp Neurology until 2008 Present. Editorial Board Parkinsonism & Related Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. BMBF Kompetenznetz Degenerative Demenzen ?Langzeitbeobachtung dementieller Sym-ptome und cognitiver Parameter sowie Anwendbarkeit neuer prognostischer Marker bei der Parkinson-Erkrankung (LANDSCAPE)?, 2012 ? 2014 EU Joint Programme Neurodegenerative Disease Research (JPND) ?Biomarkers for Alzhei-mer?s disease and Parkinson?s disease (BIOMARKAPD), 2012 ? 2014 EU FP7 ?Integrated European Project on Omics Research of Rare Neuromuscular and Neu-rodegenerative Diseases (Neuromics) Patienten ohne Diagnose: Aufbau einer Interdisziplin?ren Kompetenzeinheit zur Erkennung Seltener chronischer Erkrankungen, Robert Bosch-Stiftung, 2013 ? 2015. JPND/BMBF: European SCA3/MJD Inititiative (ESMI), 2016 - 2019 BMBF: Integrated Data Semantics, 2016 - 2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Cornelia Kornblum, MD, PhD
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Commercial company: Sanofi-Genzyme, travel funding (2) Commercial company: Sanofi-Genzyme, speaker honoraria (3) Non-profit organisation: Marigold Foundation Canada, travel funding (4) Non-profit organisation: Deutsche Gesellschaft f?r Muskelkranke e.V., travel funding

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) BMBF (German Federal Ministry of Education and Research), mitoNET, BMBF - 01GM0862, patient recruitment, 2010 - 2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Non-profit organisation: Marigold Foundation, Canada (2) Non-profit-organisation: Deutsche Gesellschaft f?r Muskelkranke e.V., grant number Me4/1

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the University Hospital of Bonn (E.H., A.B., A.M., T.K., C.K.) and the German Center for Neurodegenerative Diseases (T.K.), Bonn, Germany.
  1. Correspondence to Dr. Hattingen: elke.hattingen{at}ukb.uni-bonn.de
View Full Text

Article usage

Article usage: October 2016 to December 2020

AbstractFullPdfSource
Oct 20161952635Highwire
Nov 2016653126205Highwire
Dec 20161023343Highwire
Jan 2017341419Highwire
Feb 2017321712Highwire
Mar 2017202112Highwire
Apr 201716108Highwire
May 20171445Highwire
Jun 20171544Highwire
Jul 2017932Highwire
Aug 20171361Highwire
Sep 20171738Highwire
Oct 2017622Highwire
Nov 2017468Highwire
Dec 2017196Highwire
Jan 20183106Highwire
Feb 20181155Highwire
Mar 20183293Highwire
Apr 20181394Highwire
May 20181355Highwire
Jun 20180509Highwire
Jul 20180282Highwire
Aug 20180180Highwire
Sep 20181374Highwire
Oct 20183377Highwire
Nov 20182385Highwire
Dec 20181225Highwire
Jan 20190141Highwire
Feb 20194344Highwire
Mar 20193156Highwire
Apr 20190118Highwire
May 20192147Highwire
Jun 20190204Highwire
Jul 201911714Highwire
Aug 20192105Highwire
Sep 20191115Highwire
Oct 20192196Highwire
Nov 20192175Highwire
Dec 20191123Highwire
Jan 20203107Highwire
Feb 20201103Highwire
Mar 20200166Highwire
Apr 202001411Highwire
May 20201304Highwire
Jun 20202239Highwire
Jul 202021911Highwire
Aug 2020095Highwire
Sep 20204115Highwire
Oct 202021412Highwire
Nov 20200169Highwire
Dec 202042221Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me